King, Rebecca L.
Hsi, Eric D.
Chan, Wing C.
Piris, Miguel A.
Cook, James R.
Scott, David W.
Swerdlow, Steven H.
Article History
Received: 17 June 2022
Revised: 19 August 2022
Accepted: 23 August 2022
First Online: 3 September 2022
Declarations
:
: The authors declare the following conflicts of interest.<b>DWS:</b> Consulting: Abbvie, AstraZeneca, Incyte, Janssen.Research funding: Janssen, NanoString Technologies, Roche.Patents: named inventor on patents describing using gene expression to subtype B-cell lymphomas, including one licensed to NanoString Technologies.<b>MAP</b>: has served on the advisory board for Millenium/Takeda, Celgene, Gilead, Jansen, Nanotring, and Kyowa Kirin; received lecture fees from Millenium/Takeda, Kyowa Kirin, EUSA and Jansen; and received research funding from Millenium/Takeda, Gilead, and Kura.<b>EDH</b>: Research funding: Eli Lilly, Virtuoso. Advisory Boards: Abcon, Cytomx, Astellas, Novartis.<b>RLK</b>, <b>SHS</b>, <b>JRC</b>, and <b>WCC</b> have no conflicts or competing interests to disclose.